Eli Lilly: encouraging results in type 2 diabetes

(CercleFinance.com) - Eli Lilly announces that a Phase III study has showed that three doses of tirzepatide (5, 10 and 15mg) generated significant reductions in liver fat and abdominal adipose tissue compared to insulin degludec in adults with type 2 diabetes.


In addition, another substudy showed that all three doses improved glycaemic variability in adults with type 2 diabetes.

Tirzepatide helped participants have less variability in their blood sugar levels throughout the day, including spending less time below the target range and more time in a narrower target range reflecting normal blood sugar levels, said Richard Bergenstal, executive director of the Nicollet Park International Diabetes Centre.

The findings were presented today at the 57th annual meeting of the European Association for the Study of Diabetes (EASD).


Copyright (c) 2021 CercleFinance.com. All rights reserved.